UY29073A1 - Composicinn farmaceutica en forma de comprimido de recidencia gastrica conteniendo alfuzosine - Google Patents

Composicinn farmaceutica en forma de comprimido de recidencia gastrica conteniendo alfuzosine

Info

Publication number
UY29073A1
UY29073A1 UY29073A UY29073A UY29073A1 UY 29073 A1 UY29073 A1 UY 29073A1 UY 29073 A UY29073 A UY 29073A UY 29073 A UY29073 A UY 29073A UY 29073 A1 UY29073 A1 UY 29073A1
Authority
UY
Uruguay
Prior art keywords
gastric
pharmaceutical composition
recidence
compressed
alfuzosine
Prior art date
Application number
UY29073A
Other languages
English (en)
Inventor
Gerard Alaux
Estelle Chouin
Nathalie Dufresne
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34950702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29073(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY29073A1 publication Critical patent/UY29073A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Apparatuses For Bulk Treatment Of Fruits And Vegetables And Apparatuses For Preparing Feeds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composición farmacéutica en forma de un comprimido matricial de residencia gástrica que comprende un principio activo, caracterizada porque en contacto con un medio representativo del fluido gástrico, aumenta de volumen, en un porcentaje de inflado de al menos 200% después de quince minutos.
UY29073A 2004-08-19 2005-08-17 Composicinn farmaceutica en forma de comprimido de recidencia gastrica conteniendo alfuzosine UY29073A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0408986A FR2874325B1 (fr) 2004-08-19 2004-08-19 Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine

Publications (1)

Publication Number Publication Date
UY29073A1 true UY29073A1 (es) 2006-03-31

Family

ID=34950702

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29073A UY29073A1 (es) 2004-08-19 2005-08-17 Composicinn farmaceutica en forma de comprimido de recidencia gastrica conteniendo alfuzosine

Country Status (23)

Country Link
US (1) US20070190140A1 (es)
EP (1) EP1781295A1 (es)
JP (1) JP5048492B2 (es)
KR (1) KR20070046124A (es)
CN (1) CN101022808B (es)
AR (1) AR050696A1 (es)
AU (1) AU2005276307B2 (es)
BR (1) BRPI0514532A (es)
CA (1) CA2577361C (es)
EA (1) EA012981B1 (es)
FR (1) FR2874325B1 (es)
HK (1) HK1112575A1 (es)
IL (1) IL181150A0 (es)
MA (1) MA28862B1 (es)
MX (1) MX2007001957A (es)
MY (1) MY145832A (es)
NO (1) NO20071315L (es)
NZ (1) NZ553673A (es)
PE (1) PE20060639A1 (es)
TW (1) TWI357329B (es)
UY (1) UY29073A1 (es)
WO (1) WO2006021692A1 (es)
ZA (1) ZA200701443B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE046465T2 (hu) 2006-12-22 2020-03-30 Ironwood Pharmaceuticals Inc Epesavat megkötõ anyagokat tartalmazó készítmények nyelõcsõ-rendellenességek kezelésére
WO2008102235A1 (en) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Controlled release formulations of alfuzosin
JP2008280251A (ja) * 2007-05-08 2008-11-20 Shin Etsu Chem Co Ltd 多層錠及びその製造方法
KR101950635B1 (ko) 2008-06-30 2019-05-20 토카겐 인크. 5-플루오르시토신 제제 및 이의 용도
JP5714562B2 (ja) * 2010-02-22 2015-05-07 第一三共株式会社 経口用徐放性固形製剤
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US10569071B2 (en) 2015-08-31 2020-02-25 Ethicon Llc Medicant eluting adjuncts and methods of using medicant eluting adjuncts
US10245034B2 (en) * 2015-08-31 2019-04-02 Ethicon Llc Inducing tissue adhesions using surgical adjuncts and medicants

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH630257A5 (en) * 1975-03-17 1982-06-15 Hoffmann La Roche Sustained release formulation
DE4036757A1 (de) * 1990-11-17 1992-05-21 Bayer Ag Antazida-zubereitung mit verlaengerter magenverweilzeit
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
SI0938318T1 (en) * 1996-08-29 2001-12-31 Sanofi Synthelabo Tablet with controlled release of alfuzosine chlorydrate
US6271278B1 (en) * 1997-05-13 2001-08-07 Purdue Research Foundation Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
FR2784583B1 (fr) * 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
DE10014588A1 (de) * 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
HUP0301465A3 (en) * 2000-06-23 2006-07-28 Teva Pharma Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6881424B1 (en) * 2000-09-05 2005-04-19 Mionix Corporation Highly acidic metalated organic acid
FR2820319B3 (fr) * 2001-02-08 2003-12-05 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu
KR20040018394A (ko) * 2001-07-04 2004-03-03 썬 파마슈티컬 인더스트리스 리미티드 위 정체 제어되는 약물 전달 계
US20040219186A1 (en) * 2001-08-16 2004-11-04 Ayres James W. Expandable gastric retention device
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030215526A1 (en) * 2002-03-08 2003-11-20 Scott Stofik Stable formulations of angiotensin converting enzyme (ACE) inhibitors

Also Published As

Publication number Publication date
EA012981B1 (ru) 2010-02-26
HK1112575A1 (en) 2008-09-12
AU2005276307A1 (en) 2006-03-02
NZ553673A (en) 2010-10-29
MA28862B1 (fr) 2007-09-03
MX2007001957A (es) 2007-04-25
EA200700217A1 (ru) 2007-08-31
CN101022808A (zh) 2007-08-22
JP2008509973A (ja) 2008-04-03
FR2874325A1 (fr) 2006-02-24
TW200618802A (en) 2006-06-16
TWI357329B (en) 2012-02-01
BRPI0514532A (pt) 2008-06-17
FR2874325B1 (fr) 2006-10-20
AR050696A1 (es) 2006-11-15
NO20071315L (no) 2007-03-09
MY145832A (en) 2012-04-30
IL181150A0 (en) 2007-07-04
PE20060639A1 (es) 2006-07-20
CN101022808B (zh) 2013-05-29
WO2006021692A8 (fr) 2007-04-12
US20070190140A1 (en) 2007-08-16
EP1781295A1 (fr) 2007-05-09
CA2577361C (fr) 2013-10-01
CA2577361A1 (fr) 2006-03-02
ZA200701443B (en) 2008-05-25
WO2006021692A1 (fr) 2006-03-02
KR20070046124A (ko) 2007-05-02
JP5048492B2 (ja) 2012-10-17
AU2005276307B2 (en) 2011-02-24

Similar Documents

Publication Publication Date Title
UY29073A1 (es) Composicinn farmaceutica en forma de comprimido de recidencia gastrica conteniendo alfuzosine
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
GB2446321B8 (en) High pressure pump controller.
EP1594454A4 (en) FILMOGENIC HYDRO-ALCOHOLIC FOAM
BRPI0815577A2 (pt) Peptídeo foxm1 e agente medicinal compreendendo o mesmo.
HK1200054A1 (zh) 用於活體外器官護理的系統和方法
WO2009013435A3 (fr) Solution ophtalmique à base de prostaglandines sans conservateur
WO2005120387A3 (en) Oral care device
EP1594477A4 (en) ACTIVE MEDICATION CONTRIBUTION IN THE DIGESTIVE TUBE
MX2007002189A (es) Sales de dicetopiperazina, sales de dicetomorfolina o sales de dicetodioxano para suministro de farmacos.
HK1118011A1 (zh) 透明質酸的抗腫瘤生物結合物或以化學接合方法間接地取得的衍生物，以及其製藥用途
BRPI0815578A2 (pt) Peptídeo de cdca1 e agente farmacêutico compreendendo o mesmo.
MX2008001597A (es) Formulaciones novedosas que comprenden fenofibrato y una estatina y metodos relacionados de tratamiento.
EP1819323A4 (en) PHARMACEUTICAL COMPOSITION WITH ANTI-SKIN COMPOSER
WO2008004148A3 (fr) Dispositif médical pour l'administration d'une solution
ATE491485T1 (de) Implantierbares arzneiabgabegerät
HK1115315A1 (en) Tablet containing hardly soluble active ingredient
EP1610044A3 (en) A fluid cutoff device
PT1713438E (pt) Sabonete medicinal
IS8428A (is) Innrennslislyf sem inniheldur (2R)-2-própýloktansýru sem virka efnisþáttinn
MX2007007355A (es) 5-(2,2-dimetil-ciclopropil)-3-metil-pen-2-en nitrilo como fragancia y sabor.
TW200720273A (en) Pharmaceutically active spiro-benzimidazoles
GEP20104911B (en) Medicinal agent for preventing progression of apoptotic and jugulating necrotic changes in the organism tissues
UY29386A1 (es) Utilizción de rimonabant para la preparación de medicamentos útiles en la prevención y el tratamiento de la diabetes de tipo2.
NO20064858L (no) Nye assosiasjon mellom en heterosyklisk forbindelse og et antioksidantmiddel, og farmasoytiske sammensetninger inneholdende dem

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160530